Natasha Martin

Title(s)Associate Professor, Medicine
SchoolHealth Sciences
Address9500 Gilman Drive #0507
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oxford University, Oxford, UKDPhil/PhD2009Mathematical biology
    Stanford University, Palo Alto, CABS2003Mathematics, biology
    Collapse Awards and Honors
    2016Selected by The Economist Magazine as an "HCV Changemaker"

    Collapse Overview 
    Collapse Overview
    Dr. Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is currently an Associate Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and holds an honorary senior lecturer position at the University of Bristol. She is also the co-director of the Biostatistics and Modeling Core of the University of California San Diego Center for AIDS Research (UCSD CFAR). She has worked for 18 years developing mathematical models of disease progression and transmission in both communicable and non-communicable diseases. For the past eight years, her primary research has focused on modeling hepatitis C virus (HCV) and HIV transmission and prevention among high-risk groups such as people who inject drugs (PWID), men who have sex with men, and female sex workers. She is a leading researcher on modeling the impact of HCV treatment as prevention. Additionally, she has experience developing dynamic cost-effectiveness evaluations of case-finding and prevention interventions, and has the only published cost-effectiveness models of HCV case-finding interventions and treatment including both individual and population benefits. She is the principal investigator (PI) of a NIAID/NIDA-funded R01 optimizing HIV and HCV prevention portfolios among people who inject drugs in 108 countries. Her modeling work informed the WHO guidelines “When to start ART in people living with HIV (2013)”, and her work on the impact and cost-effectiveness of HCV treatment among people who inject drugs informed the WHO guidelines on “Hepatitis C testing, care, and treatment (2013)”. More recently, her modeling work on HCV elimination was used to inform the WHO “Global Health Sector Strategy on Viral Hepatitis 2016-2021”.

    Collapse Research 
    Collapse Research Activities and Funding
    Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling
    NIH/NIAID R01AI147490Aug 7, 2019 - Jul 31, 2023
    Role: Principal Investigator
    University of California, San Diego, Center for AIDS Research
    NIH 5 P30 AI036214Apr 1, 2018 - Mar 31, 2023
    Role: Co-Director, Biostatistics and Modeling Core
    Modeling Structural HIV Determinants in Substance Users and related populations
    NIH/NIDA R01DA037773Apr 1, 2015 - Dec 31, 2017
    Role: Principal Investigator
    Modeling opioid overdose and prevention in Australia
    Australian NHMRC Dec 31, 2023
    Role: Co-I
    Evaluating the Population Impact of Hepatitis C Direct Acting Antiviral Treatment as Prevention for People Who Inject Drugs (EPIToPe).
    UK National Institute for Health Research Feb 1, 2023
    Role: Co-investigator
    HCV elimination among men who have sex with men in Germany
    Gilead Jun 1, 2022
    Role: Co-investigator
    Impact of direct acting antivirals uptake in controlling hepatitis C epidemic and modeling interventions for hepatitis C elimination among HIV-infected persons in San Diego
    Gilead Jan 1, 2021
    Role: Co-PI
    Modeling HCV elimination among HIV-infected men who have sex with men and people who inject drugs
    Gilead Dec 31, 2020
    Role: Principal Investigator
    Testing and comparing study designs for evaluating HCV treatment as prevention (TasP) impact in a real world setting
    Merck Dec 1, 2020
    Role: Principal Investigator
    Texting intervention to sustain HIV prevention in women in high-drug-use contexts
    NIH/NIDA Jun 1, 2020
    Role: Co-investigator
    Cost-effectiveness of HCV testing and treatment in pregnant women
    Gilead Apr 30, 2020
    Role: Principal Investigator
    Surveillance and Treatment of Prisoners with hepatitis C (STOP-C)
    Australian NHMRC Dec 31, 2019
    Role: Co-Investigator
    Role Description: To test HCV treatment as prevention among prisoners in New South Wales, Australia. Overseeing modeling to inform trial design, implementation and evaluation.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Editorial: Introducing the IJDP special collection "The use of mathematical modeling to inform drug policy making". Int J Drug Policy. 2020 Apr 17; 102759. Martin NK, Vickerman P. PMID: 32312601.
      View in: PubMed   Mentions:    Fields:    
    2. Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clin Infect Dis. 2020 Apr 13. Chaillon A, Wynn A, Kushner T, Reau N, Martin NK. PMID: 32282879.
      View in: PubMed   Mentions:    Fields:    
    3. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. Int J Drug Policy. 2020 Mar 09; 102710. Marquez LK, Cepeda JA, Bórquez A, Strathdee SA, Gonzalez-Zúñiga PE, Fleiz C, Rafful C, Garfein RS, Kiene SM, Brodine S, Martin NK. PMID: 32165050.
      View in: PubMed   Mentions:    Fields:    
    4. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. Lancet Glob Health. 2020 Mar; 8(3):e440-e450. Lim AG, Walker JG, Mafirakureva N, Khalid GG, Qureshi H, Mahmood H, Trickey A, Fraser H, Aslam K, Falq G, Fortas C, Zahid H, Naveed A, Auat R, Saeed Q, Davies CF, Mukandavire C, Glass N, Maman D, Martin NK, Hickman M, May MT, Hamid S, Loarec A, Averhoff F, Vickerman P. PMID: 32087176.
      View in: PubMed   Mentions:    Fields:    
    5. Prisons can also improve drug user health in the community. Addiction. 2020 05; 115(5):914-915. Martin NK, Hickman M, Spaulding AC, Vickerman P. PMID: 32026531.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    6. Cost-effectiveness of the HepCATT intervention in specialist drug clinics to improve case-finding and engagement with HCV treatment for people who inject drugs in England. Addiction. 2020 Jan 26. Ward Z, Reynolds R, Campbell L, Martin NK, Harrison G, Irving W, Hickman M, Vickerman P. PMID: 31984606.
      View in: PubMed   Mentions:    Fields:    
    7. Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine. 2020 Feb; 19:100217. Macgregor L, Desai M, Martin NK, Nicholls J, Hickson F, Weatherburn P, Hickman M, Vickerman P. PMID: 32140664.
      View in: PubMed   Mentions:
    8. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health. 2020 Feb; 8(2):e244-e253. Walker JG, Kuchuloria T, Sergeenko D, Fraser H, Lim AG, Shadaker S, Hagan L, Gamkrelidze A, Kvaratskhelia V, Gvinjilia L, Aladashvili M, Asatiani A, Baliashvili D, Butsashvili M, Chikovani I, Khonelidze I, Kirtadze I, Kuniholm MH, Otiashvili D, Sharvadze L, Stvilia K, Tsertsvadze T, Zakalashvili M, Hickman M, Martin NK, Morgan J, Nasrullah M, Averhoff F, Vickerman P. PMID: 31864917.
      View in: PubMed   Mentions: 1     Fields:    
    9. Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Med. 2019 11; 16(11):e1002973. Marks C, Borquez A, Jain S, Sun X, Strathdee SA, Garfein RS, Milloy MJ, DeBeck K, Cepeda JA, Werb D, Martin NK. PMID: 31770373.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895. Chaillon A, Rand EB, Reau N, Martin NK. PMID: 30689769.
      View in: PubMed   Mentions: 2     Fields:    
    11. Responding to global stimulant use: challenges and opportunities. Lancet. 2019 11 02; 394(10209):1652-1667. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran LT, Rehm J, Torrens M, Shoptaw S, McKetin R. PMID: 31668409.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. J Infect Dis. 2019 10 08; 220(10):1635-1644. Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P. PMID: 31301142.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. J Viral Hepat. 2019 12; 26(12):1388-1403. Trickey A, Fraser H, Lim AG, Walker JG, Peacock A, Colledge S, Leung J, Grebely J, Larney S, Martin NK, Degenhardt L, Hickman M, May MT, Vickerman P. PMID: 31392812.
      View in: PubMed   Mentions: 1     Fields:    
    14. Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. Am J Epidemiol. 2019 08 01; 188(8):1539-1551. Fraser H, Vellozzi C, Hoerger TJ, Evans JL, Kral AH, Havens J, Young AM, Stone J, Handanagic S, Hariri S, Barbosa C, Hickman M, Leib A, Martin NK, Nerlander L, Raymond HF, Page K, Zibbell J, Ward JW, Vickerman P. PMID: 31150044.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open. 2019 06 28; 9(6):e030183. Martin NK, Vickerman P, Khakoo S, Ghosh A, Ramsay M, Hickman M, Williams J, Miners A. PMID: 31256040.
      View in: PubMed   Mentions:    Fields:    
    16. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS One. 2019; 14(6):e0217964. Chaillon A, Mehta SR, Hoenigl M, Solomon SS, Vickerman P, Hickman M, Skaathun B, Martin NK. PMID: 31170246.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019 06; 4(6):435-444. Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. PMID: 30981685.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000-2015. Open Forum Infect Dis. 2019 Apr; 6(4):ofz160. Chaillon A, Sun X, Cachay ER, Looney D, Wyles D, Garfein RS, Martin TCS, Jain S, Mehta SR, Smith DM, Little SJ, Martin NK. PMID: 31041355.
      View in: PubMed   Mentions:
    19. Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. BMJ Open. 2019 01 29; 9(1):e026298. Cepeda JA, Burgos JL, Kahn JG, Padilla R, Meza Martinez PE, Segovia LA, Gaines T, Abramovitz D, Rangel G, Magis-Rodriguez C, Vickerman P, Strathdee SA, Martin NK. PMID: 30700490.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. J Theor Biol. 2019 11 21; 481:194-201. Pitcher AB, Borquez A, Skaathun B, Martin NK. PMID: 30452959.
      View in: PubMed   Mentions:    Fields:    
    21. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018 12; 18(12):1397-1409. Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, Trickey A, Abbott S, Strathdee SA, Abramovitz D, Maher L, Iversen J, Bruneau J, Zang G, Garfein RS, Yen YF, Azim T, Mehta SH, Milloy MJ, Hellard ME, Sacks-Davis R, Dietze PM, Aitken C, Aladashvili M, Tsertsvadze T, Mravcík V, Alary M, Roy E, Smyrnov P, Sazonova Y, Young AM, Havens JR, Hope VD, Desai M, Heinsbroek E, Hutchinson SJ, Palmateer NE, McAuley A, Platt L, Martin NK, Altice FL, Hickman M, Vickerman P. PMID: 30385157.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    22. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis. 2018 10; 24(10):1806-1815. Garfein RS, Liu L, Cuevas-Mota J, Collins K, Muñoz F, Catanzaro DG, Moser K, Higashi J, Al-Samarrai T, Kriner P, Vaishampayan J, Cepeda J, Bulterys MA, Martin NK, Rios P, Raab F. PMID: 30226154.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    23. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver Int. 2019 01; 39(1):20-30. Day E, Hellard M, Treloar C, Bruneau J, Martin NK, Øvrehus A, Dalgard O, Lloyd A, Dillon J, Hickman M, Byrne J, Litwin A, Maticic M, Bruggmann P, Midgard H, Norton B, Trooskin S, Lazarus JV, Grebely J. PMID: 30157316.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    24. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health. 2018 09; 3(9):e429-e437. Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, Rafful C, Morales M, Cepeda J, Panagiotoglou D, Krebs E, Vickerman P, Claude Boily M, Thomson N, Martin NK. PMID: 30122559.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    25. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018 07 28; 392(10144):312-358. Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C. PMID: 30032975.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    26. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV. 2018 10; 5(10):e578-e587. Cepeda JA, Eritsyan K, Vickerman P, Lyubimova A, Shegay M, Odinokova V, Beletsky L, Borquez A, Hickman M, Beyrer C, Martin NK. PMID: 30033374.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction. 2018 11; 113(11):2118-2131. Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, Taylor A, Hickman M, Hutchinson S, Vickerman P. PMID: 29781207.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    28. Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infect Dis Clin North Am. 2018 06; 32(2):395-405. Martin TCS, Rauch A, Salazar-Vizcaya L, Martin NK. PMID: 29778262.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    29. Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. Harm Reduct J. 2018 05 23; 15(1):28. Burgos JL, Cepeda JA, Kahn JG, Mittal ML, Meza E, Lazos RRP, Vargas PC, Vickerman P, Strathdee SA, Martin NK. PMID: 29792191.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? J Int AIDS Soc. 2018 04; 21 Suppl 2:e25062. Martin NK, Boerekamps A, Hill AM, Rijnders BJA. PMID: 29633560.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    31. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. Int J Epidemiol. 2018 04 01; 47(2):550-560. Lim AG, Qureshi H, Mahmood H, Hamid S, Davies CF, Trickey A, Glass N, Saeed Q, Fraser H, Walker JG, Mukandavire C, Hickman M, Martin NK, May MT, Averhoff F, Vickerman P. PMID: 29309592.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    32. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018 03; 68(3):402-411. Fraser H, Martin NK, Brummer-Korvenkontio H, Carrieri P, Dalgard O, Dillon J, Goldberg D, Hutchinson S, Jauffret-Roustide M, Kåberg M, Matser AA, Maticic M, Midgard H, Mravcik V, Øvrehus A, Prins M, Reimer J, Robaeys G, Schulte B, van Santen DK, Zimmermann R, Vickerman P, Hickman M. PMID: 29080808.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. Int J Epidemiol. 2017 10 01; 46(5):1582-1592. MacGregor L, Martin NK, Mukandavire C, Hickson F, Weatherburn P, Hickman M, Vickerman P. PMID: 28605503.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    34. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction. 2018 Jan; 113(1):173-182. Fraser H, Zibbell J, Hoerger T, Hariri S, Vellozzi C, Martin NK, Kral AH, Hickman M, Ward JW, Vickerman P. PMID: 28734093.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    35. HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence. Int J Epidemiol. 2017 04 01; 46(2):466-478. Fraser H, Mukandavire C, Martin NK, Hickman M, Cohen MS, Miller WC, Vickerman P. PMID: 27524816.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Rev. 2017 Apr - Jun; 19(2):97-104. Martin NK, Skaathun B, Vickerman P, Stuart D. PMID: 28534885.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. How to eliminate HCV infection by antiviral treatment. J Hepatol. 2017 07; 67(1):5-6. Martin NK, Vickerman P, Hickman M. PMID: 28323120.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    38. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017 Jul; 112(7):1302-1314. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, Munro A, Dunleavy K, Peters E, Bramley P, Hayes PC, Goldberg DJ, Vickerman P. PMID: 28257600.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    39. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016 Oct 13; 355:i5170. Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. PMID: 27737834.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansPHPublic Health
    40. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat. 2016 12; 23(12):1009-1016. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, Bramley P, Peters SE, Valerio H, Tomnay J, Goldberg DJ, Mills PR, Barclay ST, Fraser A, Dillon JF, Martin NK, Hickman M, Hutchinson SJ. PMID: 27509844.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    41. Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction. 2017 02; 112(2):201-203. Hickman M, Martin NK, Huxtable R. PMID: 27514647.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016 Sep 17; 388(10050):1228-48. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H, Dolan K, Vickerman P. PMID: 27427455.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    43. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016 Sep 10; 388(10049):1081-1088. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. PMID: 27394647.
      View in: PubMed   Mentions: 179     Fields:    Translation:Humans
    44. Reply. Hepatology. 2016 11; 64(5):1822-1823. Martin NK, Vickerman P, Hickman M. PMID: 27112633.
      View in: PubMed   Mentions:    Fields:    
    45. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals? PLoS One. 2016; 11(5):e0156213. Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P. PMID: 27224423.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsPHPublic Health
    46. Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction. 2016 09; 111(9):1512-5. Martin NK, Vickerman P, Hickman M, Patterson TL, Rand E, Abramovitz D, Strathdee SA. PMID: 27075692.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat. 2016 08; 23(8):631-43. Harris RJ, Martin NK, Rand E, Mandal S, Mutimer D, Vickerman P, Ramsay ME, De Angelis D, Hickman M, Harris HE. PMID: 27025238.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    48. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology. 2016 06; 63(6):1796-808. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena S, Hutchinson SJ, Mandal S, O'Moore E, Hickman M. PMID: 26864802.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    49. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clin Infect Dis. 2016 May 01; 62(9):1072-1080. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, Martin TCS, Delpech V, Ruf M, Price H, Azad Y, Thomson EC, Vickerman P. PMID: 26908813.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    50. Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol. 2016 07; 65(1):17-25. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ, Goldberg DJ, Martin TCS, Ramsay M, Hickman M. PMID: 26867489.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    51. Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques. PLoS One. 2015; 10(12):e0145022. Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin NK, Fenwick E, Goldberg D. PMID: 26689908.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    52. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis. 2015 Dec; 28(6):576-82. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. PMID: 26524330.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    53. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015 Sep; 10(5):374-80. Martin NK, Vickerman P, Dore GJ, Hickman M. PMID: 26248124.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    54. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med. 2015 Aug 20; 13:198. Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M. PMID: 26289050.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsPHPublic Health
    55. STI/HIV test result disclosure between female sex workers and their primary, non-commercial male partners in two Mexico-US border cities: a prospective study. Sex Transm Infect. 2015 May; 91(3):207-13. Pines HA, Patterson TL, Rangel G, Martinez G, Bazzi AR, Ulibarri MD, Syvertsen JL, Martin NK, Strathdee SA. PMID: 25298381.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    56. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat. 2015 Apr; 22(4):399-408. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M. PMID: 25288193.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    57. Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India. PLoS One. 2014; 9(10):e107066. Panovska-Griffiths J, Vassall A, Prudden HJ, Lépine A, Boily MC, Chandrashekar S, Mitchell KM, Beattie TS, Alary M, Martin NK, Vickerman P. PMID: 25271808.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    58. Glucose-lactate metabolic cooperation in cancer: insights from a spatial mathematical model and implications for targeted therapy. J Theor Biol. 2014 Nov 21; 361:190-203. McGillen JB, Kelly CJ, Martínez-González A, Martin NK, Gaffney EA, Maini PK, Pérez-García VM. PMID: 25264268.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    59. HCV treatment as prevention in prison: key issues. Hepatology. 2015 Jan; 61(1):402-3. Martin NK, Vickerman P, Goldberg D, Hickman M. PMID: 24797358.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS. 2014 Jan; 28 Suppl 1:S35-46. Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R, Vickerman P. PMID: 24468945.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    61. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2013 Dec 10; 2(1):23-34. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. PMID: 25083415.
      View in: PubMed   Mentions: 9     Fields:    
    62. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014 Jan; 2(1):e23-34. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. PMID: 25104632.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    63. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014; 21(9):616-23. Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. PMID: 24215210.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    64. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS. 2013 Oct 23; 27(16):2551-7. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, Gazzard BG, Nelson M. PMID: 23736152.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    65. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013 Nov; 58(5):1598-609. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. PMID: 23553643.
      View in: PubMed   Mentions: 126     Fields:    Translation:Humans
    66. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013 Aug 13; 3(8). Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. PMID: 23943776.
      View in: PubMed   Mentions: 21     Fields:    
    67. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013 Aug; 57 Suppl 2:S39-45. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. PMID: 23884064.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansPHPublic Health
    68. Atraumatic splenic rupture secondary to chronic HIV infection. Int J STD AIDS. 2013 Dec; 24(12):989-91. Martin TC, Martin NK, Naresh KN, Nelson M. PMID: 23970617.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    69. How cost-effective is hepatitis C virus treatment for people who inject drugs? J Gastroenterol Hepatol. 2013 Apr; 28(4):590-2. Martin NK, Vickerman P, Miners A, Hickman M. PMID: 23527756.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. A general reaction-diffusion model of acidity in cancer invasion. J Math Biol. 2014 Apr; 68(5):1199-224. McGillen JB, Gaffney EA, Martin NK, Maini PK. PMID: 23536240.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    71. Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend. 2013 Sep 01; 132(1-2):172-81. Vickerman P, Martin NK, Roy A, Beattie T, Jarlais DD, Strathdee S, Wiessing L, Hickman M. PMID: 23453261.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    72. C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection. Eur J Gastroenterol Hepatol. 2013 Jan; 25(1):33-6. Farne HA, Martin NK, Main J, Orchard T, Tyrrell-Price J. PMID: 23026925.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    73. Could low dead-space syringes really reduce HIV transmission to low levels? Int J Drug Policy. 2013 Jan; 24(1):8-14. Vickerman P, Martin NK, Hickman M. PMID: 23206493.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsPHPublic Health
    74. Pancreatic insufficiency in patients with HIV infection: role of didanosine questioned. HIV Med. 2013 Mar; 14(3):161-6. Martin TC, Scourfield A, Rockwood N, Martin NK, Patel N, Nelson M, Gazzard BG. PMID: 22994793.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    75. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust. 2012 Jun 04; 196(10):638-41. Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK. PMID: 22676879.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    76. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br J Cancer. 2012 Mar 27; 106(7):1280-7. Martin NK, Robey IF, Gaffney EA, Gillies RJ, Gatenby RA, Maini PK. PMID: 22382688.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    77. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012 Jan; 55(1):49-57. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. PMID: 21898506.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansPHPublic Health
    78. Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact. Drug Alcohol Depend. 2012 Jun 01; 123(1-3):122-31. Vickerman P, Martin NK, Hickman M. PMID: 22138540.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    79. Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One. 2011; 6(8):e22309. Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M. PMID: 21853030.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    80. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer. 2011 Jun 10; 11:235. Robey IF, Martin NK. PMID: 21663677.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    81. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011 Jun; 54(6):1137-44. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. PMID: 21145810.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    82. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol. 2011 Apr 07; 274(1):58-66. Martin NK, Vickerman P, Hickman M. PMID: 21236265.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    83. A mathematical model of tumour and blood pHe regulation: The HCO3-/CO2 buffering system. Math Biosci. 2011 Mar; 230(1):1-11. Martin NK, Gaffney EA, Gatenby RA, Gillies RJ, Robey IF, Maini PK. PMID: 21167185.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    84. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J Theor Biol. 2010 Dec 07; 267(3):461-70. Martin NK, Gaffney EA, Gatenby RA, Maini PK. PMID: 20816684.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    85. Leaky vessels as a potential source of stromal acidification in tumours. J Theor Biol. 2010 Dec 07; 267(3):454-60. Martin NK, Gaffney EA, Gatenby RA, Maini PK. PMID: 20699102.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    Natasha's Networks
    Concepts (269)
    Derived automatically from this person's publications.
    Co-Authors (29)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department